EarlyCDT®-Lung is designed to aid in the risk assessment and early detection of lung cancer. While everyone carries some risk of developing lung cancer, you could be at increased risk if you answer “yes” to one or more of the following questions.
The process recommended by your health-care provider is designed to detect a lung tumor early. It is important to remember that EarlyCDT-Lung has been developed to help detect the presence of autoantibodies to tumor antigens which have been reported to be detectable up to five years before a tumor has become definable.1
This is not meant to be a comprehensive questionnaire. Please talk to your physician about your risk of developing lung cancer.
US Patent No 7,402,403